The pharmaceutical companies behind Ozempic, Wegovy and other weight-loss meds push to prevent compounding pharmacies from ...

“The average woman gains about six to seven pounds during this menopausal transitional period,” says Daniel H. Bessesen, MD, ...

Novo Nordisk stock has been pretty volatile lately, making it hard to judge whether now is a good opportunity to buy shares.

Hi, it's Amber in Hong Kong. Blockbuster weight-loss drug Wegovy is going to be much cheaper in China than it is in the US.

Old Town Med Spa is among those being accused of using false advertising and deceptive marketing practices to sell ...

Ozempic is approved only for treating Type 2 diabetes but claims about its weight-loss powers have seen demand soar, ...

A month’s supply of semaglutide lozenges with vitamin B6 added from the telehealth startup Strut, for example, costs $149 ...

A groundbreaking Harvard study reveals that semaglutide could benefit more people in the U.S. than ever imagined.

Driving business growth through innovative food and nutrition strategies for CPG & foodservice brands. 💡 The Rise of GLP-1 ...

Study estimates 136.8 million U.S. adults are eligible for semaglutide, a popular therapy for diabetes, weight loss, and cardiovascular disease.

Stroke was the fourth leading cause of death in the U.S. in 2023, according to the Centers for Disease Control and Prevention ...

More than half of all American adults, almost 137 million people, could be candidates for the blockbuster GLP-1 drug ...